Lithium carbonate 200 mg Extended Release Oral Tablet
RxNorm 248306
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 248306 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: lithium carbonate 200 mg Extended Release Oral Tablet.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SCD
Semantic Clinical Drug (SCD):
Lithium carbonate 200 mg Extended Release Oral Tablet
(Atom ID: 12348475)
SY
Synonym (SY):
LiCO3 200 mg Extended Release Oral Tablet
(Atom ID: 6353876)
PSN
Prescribable Name (PSN):
Lithium carbonate 200 mg Extended Release Oral Tablet
(Atom ID: 6361603)
PT
Designated preferred name (PT):
Lithium carbonate 200 mg prolonged-release oral tablet
(Atom ID: 10301026)
FN
Full form of descriptor (FN):
Product containing precisely lithium carbonate 200 mg/1 each prolonged-release oral tablet (clinical drug)
(Atom ID: 10314339)
Patient Education
Lithium
Lithium is used to treat and prevent episodes of mania (frenzied, abnormally excited mood) in people with bipolar disorder (manic-depressive disorder; a disease that causes episodes of depression, episodes of mania, and other abnormal moods). Lithium is in a class of medications called antimanic agents. It works by decreasing abnormal activity in the brain.
[Learn More]
* Please review the disclaimer below.